We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+2.62%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.41B
AUM Growth
+$445M
Cap. Flow
+$949M
Cap. Flow %
14.82%
Top 10 Hldgs %
42.9%
Holding
120
New
18
Increased
32
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$365M
2
QDEL icon
QuidelOrtho
QDEL
+$162M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$67.4M
4
PTCT icon
PTC Therapeutics
PTCT
+$63.7M
5
ITOS
iTeos Therapeutics
ITOS
+$61M

Top Sells

Rank Stock Value
1
KRRO icon
Korro Bio
KRRO
+$86.8M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$73.8M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$42.8M
4
IMVT icon
Immunovant
IMVT
+$32.6M
5
PEN icon
Penumbra
PEN
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.33%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PROF
101
Profound Medical
PROF
$269M
$2.46M 0.04%
122,098
– –
TWST icon
102
Twist Bioscience
TWST
$7.25B
$2.29M 0.04%
18,473
– –
VINCW
103
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
$2.02M 0.03%
500,000
– –
MASS icon
104
908 Devices
MASS
$364M
$1.94M 0.03%
40,000
– –
ELUT icon
105
Elutia
ELUT
$37.6M
$1.73M 0.03%
125,000
– –
BNR
106
Burning Rock Biotech
BNR
$92.9M
$808K 0.01%
3,000
– –
CEREW
107
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$718K 0.01%
166,666
– –
BCAB icon
108
BioAtla
BCAB
$5.74M
$508K 0.01%
200
– –
BIOR
109
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$476K 0.01%
400
– –
NUVB.WS
110
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$267K ﹤0.01%
+100,000
New +$289K
SEER icon
111
Seer Inc
SEER
$120M
$200K ﹤0.01%
4,000
– –
KRRO icon
112
Korro Bio
KRRO
$195M
– –
-49,230
Closed -$86.8M
OSUR icon
113
OraSure Technologies
OSUR
$279M
– –
-184,000
Closed -$1.95M
PEN icon
114
Penumbra
PEN
$12.8B
– –
-118,273
Closed -$20.7M
PHGE icon
115
BiomX
PHGE
$1.85M
– –
-3,158
Closed -$3.83M
PHGE.WS
116
DELISTED
BiomX Inc. Warrants to purchase one-half of a share of Common Stock
PHGE.WS
– –
-600,000
Closed -$480K
ODT
117
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-1,000,139
Closed -$19.2M
GNMK
118
DELISTED
GenMark Diagnostics, Inc
GNMK
– –
-762,994
Closed -$11.1M
FPRX
119
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-2,515,788
Closed -$42.8M
PANA.U
120
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
– –
-300,000
Closed -$3.83M
1 2 3 4
5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q1 2021 Portfolio in Review

As of Q1 2021, RTW Investments held 120 positions worth $6.41B, up 7.5% from $5.96B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

RTW Investments deployed $949M of net new capital in Q1 2021, opening 18 new positions and adding to 32 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 946,255 shares worth $375M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $73.8M trimmed.

  • RTW Investments's largest Q1 2021 buy was State Street SPDR S&P 500 ETF Trust: 946,255 shares worth $375M.
  • RTW Investments added most to PTC Therapeutics in Q1 2021, an estimated $63.7M increase.
  • RTW Investments's biggest Q1 2021 reduction was Rocket Pharmaceuticals, cutting an estimated $73.8M.
  • RTW Investments fully exited Korro Bio in Q1 2021, selling an estimated $86.8M.
  • RTW Investments's ten largest holdings make up 43% of its $6.41B portfolio in Q1 2021.
  • RTW Investments opened 18 new positions and closed 9 in Q1 2021.
  • RTW Investments's portfolio value rose 7.5% quarter-over-quarter to $6.41B.

Based on RTW Investments's 13F filing for Q1 2021, filed 14 May 2021.